Abstract
Topical delivery of drugs to the skin, for skin or for musculoskeletal conditions, is valued because it allows use of smaller loads of active ingredients to obtain the same effect as that obtained following oral or parenteral administration. This results in reduction of systemic side effects and avoidance of passage through the liver after intestinal absorption. The problems for this type of treatment are the possibility to control it, to evaluate the exact amount of active agent to reach each skin layer/target site, and most of all, to overcome the barrier represented by the (SC). This barrier, more efficient against hydrophilic species, allows absorption which ranges between 1 % of a dose of active (hydrocortisone) on the soles and 42 % when applied to the eyelids [1]. Moreover, in some skin diseases, due to a partially disturbed skin structure, the uptake of the topically applied medication may be high enough to produce unwanted local (rashes) or systemic side effects, while in other situations the uptake of compounds delivered as creams or gels may be lower than the effective level.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Other sources consider 500 Da as the limit
References
Schäfer-Korting M, Mehnert W, Korting H-C (2007) Lipid nanoparticles for improved topical application of drugs for skin disease. Adv Drug Deliv Rev 59:427–443
Barry BW (2004) Breaching the skin’s barrier to drugs. Nat Biotechnol 22:165–167
Pardeike J, Hommoss A, Műller RH (2009) Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 366:170–184
Mandawgade SD, Patravale VB (2008) Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm 363:132–138
Mehnert W, Mäder K (2001) Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47:165–196
Priano L, Esposti D, Castagna G, DeMedici C, Fraschini F, Gasco MR, Mauro A (2007) Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. J Nanosci Nanotechnol 7:3596–3601
Schubert MA, Műller-Goyman CC (2003) Solvent injection as a new approach for manufacturing lipid nanoparticles – evaluation of the method and process parameters. Eur J Pharm Biopharm 55:125–131
Heurtauld B, Saulnier P, Pech B, Proust JE, Benoit JP (2002) A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res 19:875–880
Sjӧstrӧm B, Bergenstahl B (1992) Preparation of submicrom drug particles in lecithin-stabilized o/w emulsions. I. Model studies of the precipitation of cholesteryl acetate. Int J Pharm 88:53–62
Trotta M, Debernardi F, Caputo O (2003) Preparation of solid-lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm 257:153–160
Puglia C, Blasi P, RizzaSchoubben A, Bonina F, Rossi C, Ricci M (2008) Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm 357:295–304
El-Harati AA, Charcosset C, Fessi H (2006) Influence of the formulation for solid lipid nanoparticles prepared with a membrane contractor. Pharm Dev Technol 11:153–157
Műller RH, Radtke M, Wissing SA (2002) Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54(Suppl 1):S131–S155
Schäfer-Korting M, Mehnert W (2005) Delivery of lipophilic compounds with lipid nanoparticles – applications in dermatics and for transdermal therapy. In: Nastruzzi C (ed) Drug targets and delivery: approach, methods, and applications. CRC Press, Boca Raton, pp 127–142
Mäder K (2005) Non-invasive spectroscopic and imaging techniques in drug delivery. Adv Drug Deliv Rev 57:1083–1084
Lombardi Borgia S, Regehly M, Sivaramakrishnan R, Mehnert W, Korting HC, Danker K, Rӧder B, Kramer KD, Schäfer-Korting M (2005) Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and paraelectric spectroscopy. J Control Release 110:151–163
Wissing SA, Kayser O, Műller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257–1272
Shah KA, Date AA, Joshi MD, Patravale VB (2007) Solid lipid nanoparticles of tretinoin: potential in topical delivery. Int J Pharm 345:163–171
Wissing SA, Műller RH (2001) Solid lipid nanoparticles (SLN) – a novel carrier for UV blockers. Pharmazie 56:783–786
Fang J-Y, Fang C-L, Liu C-H, Su Y-H (2008) Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 70:633–640
Peddineni M, Tyrtova E, Balsara K, Komstead M, Benzecry A, Leonida MD (2013) Encapsulated lanthibiotics for longer shelf life of cosmetic formulations. In: Society of Cosmetic Chemists, Conference on technology transfer, Iselin, 13 November
Schwarz C, Mehnert W (1999) Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J Microencapsul 16:205–213
Santos Maia C, Mehnert W, Schaller H, Korting H, Gyler A, Haberland A, Schäfer-Korting M (2002) Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target 10:489–495
Sivaramakrishnan R, Nakamura C, Mehnert W, Korting HC, Kramer KD, Schäfer-Korting M (2004) Glucocorticoid entrapment into liquid carriers – characterization by paraelectric spectroscopy and influence on dermal uptake. J Control Release 97:493–502
Saupe A, Wissing SA, Lenk A, Schmidt C, Műller RH (2005) Solid lipid nanoparticles (SLN) and nanostructured carriers – structural investigations on two different carrier systems. Bio-Med Mater Eng 15:393–402
Műller RH, Petersen RD, Hommoss A, Pardeike J (2007) Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 59:522–530
Jenning V, Schäfer-Korting M, Gogla S (2000) Vitamin A loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release 66:115–126
Műnster U, Nakamura C, Haberland A, Jores K, Mehnert W, Rummel S, Schaller M, Korting HC, Zouboulis CC, Blume-Peytavi U, Schäfer-Korting M (2005) RU 58841-myristat- prodrug development for topical treatment of acne and androgenetic alopecia. Pharmazie 60:8–12
Patel VB, Misra A, Marfatia YS (2000) Topical liposomal gel of tretinoin for the treatment of acne: research and clinical implications. Pharm Dev Technol 5:455–464
Kalariya M, Padhi BK, Chougule M, Misra A (2005) Cobetasole propionate solid lipid nanoparticles cream for effective treatment of eczema: formulation and clinical implications. Indian J Exp Biol 43:233–240
Ceve G, Blume G (2004) Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage. Biochim Biophys Acta 1663:61–73
Williams AC, Barry BW (2004) Penetration enhancers. Adv Drug Deliv Rev 56:603–618
Műller RH, Immig H, Hommoss A (2007) Prolonged release of perfumes by nanolipid technology (NLC). Eur Cosmet 11:12–18
Iscan Y, Wissing SA, Hekimoglu S, Műller RH (2005) Solid lipid nanoparticles (SLN) for topical drug delivery: incorporation of the lipophilic drug N, N-diethylmethoxytoluamide and vitamin K. Pharmazie 60:905–909
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Leonida, M.D., Kumar, I. (2016). Lipid-Based Nanoparticles in Cosmetic and Pharmaceutical Products for the Skin. In: Bionanomaterials for Skin Regeneration. SpringerBriefs in Bioengineering. Springer, Cham. https://doi.org/10.1007/978-3-319-39168-7_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-39168-7_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-39166-3
Online ISBN: 978-3-319-39168-7
eBook Packages: EngineeringEngineering (R0)